Overactive Bladder - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 123 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Overactive Bladder - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Overactive Bladder - Pipeline Review, H1 2015', provides an overview of the Overactive Bladder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Overactive Bladder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Overactive Bladder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Overactive Bladder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Overactive Bladder Overview 10
Therapeutics Development 11
Pipeline Products for Overactive Bladder - Overview 11
Pipeline Products for Overactive Bladder - Comparative Analysis 12
Overactive Bladder - Therapeutics under Development by Companies 13
Overactive Bladder - Therapeutics under Investigation by Universities/Institutes 15
Overactive Bladder - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Overactive Bladder - Products under Development by Companies 19
Overactive Bladder - Products under Investigation by Universities/Institutes 22
Overactive Bladder - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
Allergan, Inc. 24
Asahi Kasei Pharma Corp. 25
Astellas Pharma Inc. 26
Dong-A Socio Group 27
FemmePharma Global Healthcare, Inc. 28
Ferring International Center S.A. 29
Hydra Biosciences, Inc. 30
Ion Channel Innovations, LLC 31
Ipsen S.A. 32
Jeil Pharmaceutical Co., Ltd. 33
Laboratorios SALVAT S.A. 34
Lipella Pharmaceuticals, Inc. 35
Merck & Co., Inc. 36
Mezzion Pharma Co. Ltd. 37
MI.TO. Technology S.r.L. 38
NeuroSearch A/S 39
Recordati S.p.A. 40
Sanofi 41
Takeda Pharmaceutical Company Limited 42
TARIS BioMedical, Inc. 43
TheraVida, Inc. 44
Toray Industries, Inc. 45
Overactive Bladder - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(mirabegron + solifenacin succinate) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
abobotulinumtoxin A - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ADX-71441 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
DA-8010 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
FE-999309 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HC-067047 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
JLP-1207 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
mirabegron ER - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NS-19504 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
onabotulinumtoxin A liposomal - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
oxybutynin chloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
oxybutynin hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pVAX-hSlo - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
REC-0438 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SAR-244181 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
senrebotase - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Antagonize TRPV1 for Overactive Bladder - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
solifenacin succinate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
solifenacin succinate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
tacrolimus liposomal - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
tarafenacin - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TD-302 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
THVD-201 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
THVD-202 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
udenafil - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
vibegron - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Overactive Bladder - Recent Pipeline Updates 97
Overactive Bladder - Dormant Projects 108
Overactive Bladder - Discontinued Products 114
Overactive Bladder - Product Development Milestones 116
Featured News & Press Releases 116
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 116
May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 117
Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial 117
Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder 118
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 118
May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 119
May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder 119
May 07, 2013: Astellas Pharma Presents Clinical Data On Myrbetriq At American Urological Association Annual Meeting 120
Apr 10, 2013: Astellas Introduces Myrbetriq For Canadian Patients With Overactive Bladder 120
Apr 09, 2013: Laboratorios Salvat And Kwang Dong Pharma Announce Positive Phase IIb Results Of Tarafenacin For Overactive Bladder Treatment 121
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123

List of Tables

Number of Products under Development for Overactive Bladder, H1 2015 11
Number of Products under Development for Overactive Bladder - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Development by Companies, H1 2015 (Contd..2) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H1 2015 23
Overactive Bladder - Pipeline by Allergan, Inc., H1 2015 24
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H1 2015 25
Overactive Bladder - Pipeline by Astellas Pharma Inc., H1 2015 26
Overactive Bladder - Pipeline by Dong-A Socio Group, H1 2015 27
Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H1 2015 28
Overactive Bladder - Pipeline by Ferring International Center S.A., H1 2015 29
Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H1 2015 30
Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H1 2015 31
Overactive Bladder - Pipeline by Ipsen S.A., H1 2015 32
Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 33
Overactive Bladder - Pipeline by Laboratorios SALVAT S.A., H1 2015 34
Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 35
Overactive Bladder - Pipeline by Merck & Co., Inc., H1 2015 36
Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 37
Overactive Bladder - Pipeline by MI.TO. Technology S.r.L., H1 2015 38
Overactive Bladder - Pipeline by NeuroSearch A/S, H1 2015 39
Overactive Bladder - Pipeline by Recordati S.p.A., H1 2015 40
Overactive Bladder - Pipeline by Sanofi, H1 2015 41
Overactive Bladder - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 42
Overactive Bladder - Pipeline by TARIS BioMedical, Inc., H1 2015 43
Overactive Bladder - Pipeline by TheraVida, Inc., H1 2015 44
Overactive Bladder - Pipeline by Toray Industries, Inc., H1 2015 45
Assessment by Monotherapy Products, H1 2015 46
Assessment by Combination Products, H1 2015 47
Number of Products by Stage and Target, H1 2015 49
Number of Products by Stage and Mechanism of Action, H1 2015 51
Number of Products by Stage and Route of Administration, H1 2015 53
Number of Products by Stage and Molecule Type, H1 2015 55
Overactive Bladder Therapeutics - Recent Pipeline Updates, H1 2015 97
Overactive Bladder - Dormant Projects, H1 2015 108
Overactive Bladder - Dormant Projects (Contd..1), H1 2015 109
Overactive Bladder - Dormant Projects (Contd..2), H1 2015 110
Overactive Bladder - Dormant Projects (Contd..3), H1 2015 111
Overactive Bladder - Dormant Projects (Contd..4), H1 2015 112
Overactive Bladder - Dormant Projects (Contd..5), H1 2015 113
Overactive Bladder - Discontinued Products, H1 2015 114
Overactive Bladder - Discontinued Products (Contd..1), H1 2015 115